Cartesian Stock Price, News & Analysis

Cartesian Therapeutics (NASDAQ: RNAC) has granted inducement awards to five new employees on February 3, 2025. The awards consist of options to purchase a total of 168,360 shares of company common stock at an exercise price of $19.89 per share, matching the closing price on Nasdaq Global Market on the grant date.

The options were issued under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and received board approval. The vesting schedule includes 25% vesting on February 3, 2026, followed by three equal annual installments, achieving full vesting by February 3, 2029. The options have a ten-year term and were granted under Nasdaq Listing Rule 5635(c)(4).

Cartesian Therapeutics (NASDAQ: RNAC) has secured FDA Special Protocol Assessment (SPA) agreement for its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG). The trial is scheduled to begin in first half of 2025. The SPA agreement confirms that the trial design could support a future Biologics License Application.

The Phase 3 AURORA trial will be randomized, double-blind, and placebo-controlled, involving approximately 100 participants with AChR Ab+ MG. The study will evaluate Descartes-08 versus placebo with six weekly infusions without preconditioning chemotherapy. The primary endpoint will measure improvement in MG-ADL score.

Recent Phase 2b trial results showed promising outcomes, with treated participants (n=12) achieving an average MG-ADL reduction of 5.5 at Month 4. The therapy demonstrated good tolerability, supporting outpatient administration without requiring lymphodepleting chemotherapy.

Cartesian Therapeutics (NASDAQ: RNAC) has outlined its 2025 strategic priorities for its mRNA cell therapy pipeline. The company's lead candidate, Descartes-08, showed promising Phase 2b results in myasthenia gravis (MG), with participants experiencing an average MG-ADL reduction of 5.5 at Month 4. The Phase 3 AURORA trial for MG is set to begin in 1H25.

The company is also advancing Descartes-08 in other indications, with an ongoing Phase 2 trial in systemic lupus erythematosus (SLE) expected to report data in 2H25, and plans to start a Phase 2 basket trial in pediatric autoimmune diseases in 2025. Additionally, dosing is underway in a Phase 1 trial of Descartes-15, their next-generation anti-BCMA mRNA CAR-T cell therapy.

Cartesian's cash resources are expected to support planned operations, including the Phase 3 trial completion, into mid-2027.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has granted inducement awards to three new employees. On January 2, 2025, the company issued options to purchase a total of 19,324 shares of common stock at an exercise price of $16.93 per share, matching the closing price on Nasdaq that day.

The options were granted under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and approved by the board. The vesting schedule includes 25% on January 2, 2026, followed by three equal annual installments until full vesting on January 2, 2029. The options have a ten-year term and were granted under Nasdaq Rule 5635(c)(4) as employment inducements.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has granted inducement awards to four new employees. The awards consist of options to purchase 25,602 shares of company common stock at an exercise price of $20.12, matching the closing price on Nasdaq Global Market on December 12, 2024. The options, granted under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan, will vest 25% on December 12, 2025, followed by three equal annual installments until full vesting on December 12, 2028. The ten-year options were granted under Nasdaq Listing Rule 5635(c)(4).

Cartesian Therapeutics (NASDAQ: RNAC) announced positive updated results from its Phase 2b trial of Descartes-08 for myasthenia gravis treatment. The trial showed deepening responses over time, with participants experiencing a 5.5-point reduction in MG-ADL at Month 4, and durable responses through Month 12. The company outlined its planned Phase 3 AURORA trial, set to commence in 1H2025, which will evaluate approximately 100 participants. The Phase 2b trial demonstrated a favorable safety profile supporting outpatient administration without preconditioning chemotherapy. Notably, participants without prior biologic therapy exposure showed particularly strong responses, with a 6.6-point average MG-ADL reduction at Month 4.

Cartesian Therapeutics (NASDAQ: RNAC) announced it will present updated efficacy and safety data from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit in Philadelphia. The presentation, titled 'Perspectives on Bringing Cell Therapies to the Autoimmune Space: From Concept to Clinic,' will be delivered by Chief Medical Officer Miloš Miljković on December 3, 2024. The company will host a conference call and webcast with key opinion leader Dr. James F. Howard Jr. to discuss the updated data and planned Phase 3 trial design.

Cartesian Therapeutics (NASDAQ: RNAC) has granted inducement awards to two new employees on November 4, 2024. The awards consist of options to purchase 4,854 shares of common stock at an exercise price of $19.11 per share. The options will vest 25% on November 4, 2025, followed by three equal annual installments until full vesting on November 4, 2028. These ten-year term options were granted under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Cartesian Therapeutics (NASDAQ: RNAC) reported Q3 2024 financial results and business updates. The company plans to initiate a Phase 3 trial of Descartes-08 for myasthenia gravis in 1H2025 following FDA discussions. Key highlights include: $220.9M in cash expected to support operations into mid-2027, ongoing Phase 2 trial for systemic lupus erythematosus, and first-in-human Phase 1 trial of Descartes-15. Q3 financial results show R&D expenses of $11.4M, G&A expenses of $6.6M, and a net loss of $(24.2M) or $(1.13) per share.